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2-DEOXY-D-GLUCOSE ENHANCES DICHLOROACETATE 
ANTITUMOR ACTION AGAINST LEWIS LUNG CARCINOMA
O.N. Pyaskovskaya*, D.L. Kolesnik, A.G. Fedorchuk, I.V. Prochorova, G.I. Solyanik
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine,  
Kyiv 03022, Ukraine
Aerobic glycolysis that supports high proliferation rate and survival of tumor cells in unfavorable conditions is among fundamental 
features of tumor metabolism. The search for active modulators of energetic metabolism capable of suppressing tumor growth and 
metastasis could result in higher effectiveness of anticancer therapy. Aim: To study antitumor and antimetastatic activity of the 
modulators of energetic metabolism dichloroacetate (DCA) and 2-deoxy-D-glucose (2DG) used in combination treatment 
of Lewis lung carcinoma (LLC). Materials and Methods: As experimental tumor model, LLC/R9 variant was used. DCA and 2DG 
were administered per os to С57Bl/6 mice 5 times per week for 3 weeks at a total dose of 1.5 and 0.98 g/kg, respectively, as single 
agents or in combination starting from the following day after tumor cell transplantation. Growth of primary tumor and number 
and volume of lung metastases were registered. Lactate and pyruvate content was determined by enzymatic methods using lactate 
dehydrogenase. Electron paramagnetic resonance was used for analyzing the functional state of the components of mitochondrial 
respiratory chain. Engulfing activity and reactive oxygen species (ROS) production in tumor-associated CD14+ cells was analyzed 
by flow cytometer with the use of FITC-labeled staphylococcus, and by spectrofluorometry with the use of 2.7-dichlorofluorescein 
diacetate, respectively. Results: DCA administered as a single agent did not affect primary tumor growth but decreased the number 
and volume of lung metastases by 60% (p < 0.05) and 90% (p < 0.05), respectively. In mice treated with 2DG only, primary tumor 
volume as well as the number and volume of lung metastases were not affected. Combination treatment with DCA and 2DG re-
sulted in the decrease of primary tumor volume, the number and volumes of lung metastases by 70; 46, and 90%, respectively 
(р < 0.05). High antitumor activity of DCA + 2DG was associated with 31% decrease (p < 0.05) of lactate content in tumor tissue 
and 120% increase (p < 0.01) of ROS production in СD14+ cells recruited to the region of tumor growth. Conclusion: 2DG that 
possesses neither antitumor nor antimetastatic activity against LLC/R9 significantly enhanced antitumor activity of DCA with 
accompanying inhibition of glycolysis and increase of cytotoxic activity of CD14+ cells infiltrating tumor tissue. Taking into account 
significant antimetastatic activity of DCA this substance could be considered as a promising antimetastatic agent.
Key Words: Lewis lung carcinoma, antitumor and antimetastatic action, dichloroacetate, 2-deoxy-D-glucose, reactive oxygen 
species, CD14+ macrophage-like cells.
It is well known that glycolysis is the main way 
of ATP generation in the large majority of malignant 
cells even in the presence of oxygen. Despite the 
fact that special features of tumor bioenergetics are 
being used in oncological practice for diagnostic and 
prognostic purposes since 50th of last century until 
now [1], only recently tumor metabolism has started 
to be considered as a therapeutic target [2]. As soon 
as glycolysis has been recognized as the main meta-
bolic way providing tumor cell proliferation and survival 
in unfavorable conditions, the research has been fo-
cused on the compounds capable to suppress tumor 
growth via modification of its energetic metabolism. 
Among such compounds one could mention sodium 
dichloroacetate (DCA), an inhibitor of pyruvate de-
hydrogenase (PDH) kinase, and 2-deoxy-D-glucose 
(2DG), an inhibitor of glycolysis. Usually DCA has been 
used for correction of chronic metabolic malfunctions, 
but several data [3, 4] prompted to consider DCA 
as a promising anticancer agent capable of activating 
indirectly the enzymes of PDH complex and conse-
quently shifting tumor cell metabolism from glycolysis 
to oxidative phosphorylation. 2DG is a structural ana-
log of glucose in which hydroxyl group in the second 
position is replaced with hydrogen. Due to its structure, 
2DG is irreversibly phosphorylated with hexokinase 
into 2DG-phosphate that is accumulated in a cell 
without further transformation leading to block ATP 
production via glycolysis.
Up-to-date anticancer activity of DCA and 2DG has 
been demonstrated against many types of malignant 
cells in vitro and in vivo [3, 5–7], and both compounds 
are being tested in clinical trials of phases І–ІІ [8, 9]. 
However, so far, the use of these compounds as single 
anticancer agents did not show apparently positive 
results and their effectiveness in experimental tumors 
was insufficient [10–12]. Therefore is seems reason-
able to study these compounds in combination with 
other antitumor agents to enhance their anticancer 
efficacy and to decrease their toxicity; such approach 
has shown promising results [13].
The aim of present study was to analyze antitumor 
and antimetastatic activity of DCA combined with 2DG 
against Lewis lung carcinoma (LLC).
MATERIALS AND METHODS
Experimental animals and tumor cells. The 
study was carried out on С57Bl/6 mice 2–2.5 months 
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old weighting 18.5–21.5 g, bred at animal facility 
of R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology (IEPOR, Kyiv, Ukraine). 
The use and care of the experimental animals have 
been performed in accordance with the standard in-
ternational rules of biologic ethics and was approved 
by Institutional Animal Care and Use Committee.
As experimental tumor model, we have used LLC 
variant LLC/R9, resistant to cisplatin and generated 
from the parental LLC strain by multiple sequential 
cycles of cisplatin administration to tumor-bearing 
mice in vivo [14]. LLC/R9 cells were maintained in vitro 
in RPMI 1640 culture medium (Sigma, USA) supple-
mented with 10% fetal bovine serum (FBS) (Sigma, 
USA) and 40 µg/ml gentamycin at 37 °С in humidified 
atmosphere with 5% СО2.
For in vivo experiments, LLC/R9 cells were propa-
gated in vitro at standard conditions and inoculated 
i.m. to the mice (106 cells in 0.1 ml of Hank’s solution 
per animal).
The number of cells in suspension and their viability 
were routinely evaluated using hemocytometer and 
0.4% trypan blue solution.
Agents, dosages and administration sche­
dule. DCA (Sigma, USA) and 2DG (Sigma, USA) 
were admini stered per os at total doses of 1.5 and 
0.98 g/kg, respectively (both doses corresponded 
to therapeutical range and were well tolerated [15–17]) 
at the regimens of a single use or combined treatment.
After tumor transplantation, experimental animals 
were randomly distributed in four groups: group 1 — 
mice treated with DCA (n = 11), group 2 — mice treated 
with 2DG (n = 13), group 3 — mice treated with DCA 
in combination with 2DG (n = 13). In the last case, 2DG 
was administered at least 3 h after DCA. Mice treated 
with water at the same regimen and in the same volume 
served as the control (n = 12).
Treatment with DCA and 2DG has been initiated 
on the following day after tumor cell transplantation, 
5 times per week for 3 weeks. DCA and 2DG solutions 
were prepared ex tempore in water, and were admin-
istered in a volume of 0.4 ml/animal.
Antitumor and antimetastatic activity of the 
studied compounds were evaluated on day 21 after 
tumor transplantation. Primary tumor diameter was 
measured triply per week starting from the moment 
of development of palpable tumors. Tumor volume (V) 
was calculated by the formula:
V = 0.52d3,
where d — tumor diameter.
Anticancer activity was evaluated as tumor growth 
inhibition rate calculated by the formula:
[(Vk – V) / Vk] • 100%,
where V, Vk — average tumor volumes in experi-
mental and control groups, respectively.
The number and volume of lung metastases was 
routinely analyzed using binocular microscope and 
millimeter scale.
Volume of metastases (V) was calculated by the 
formula:
V = 
1
∑
N
 π di3 / [ni × 6],
where ni — number of metastases with the dia-
meter of di.
Functional state of the components of mito­
chondrial respiratory chain of tumor cells was ana-
lyzed using electron paramagnetic resonance (EPR). 
Tumor tissue was cut into the samples of cylindrical 
shape (d = 4.0 mm, l = 25–35 mm), frozen and stored 
at −70 °C. EPR analysis of the samples was performed 
at 77 К using spectrometer Е-109 Varian (USA) at po-
tential sweep speed of 500 Е/min, modulation am-
plitude of 1.25•10 Е, power of super high frequency 
radiation of 10.0 mW, constant session of apparatus 
of 1.0 s. The levels of reduced nonheme iron-sulfur 
(Fe-S) centers (g = 1.94) of MtETC proteins, nitrosyl 
(NO) complexes of heme iron (gmed = 2.007) and non-
heme iron (gmed = 2.03) were determined by the data 
of EPR spectra.
Contents of glucose, creatinine and urea 
in blood plasma samples were determined with the use 
of semiautomatic biochemical analyzer. Blood plasma 
was prepared using heparinized tubes and stored at 
–20 °С until the time of analysis.
Glucose content in tumor tissue homogenates 
was determined by enzyme glucose-oxidant method 
using the kit for glucose analysis in biologic fluids 
(Sigma, USA) according to instructions of the manu-
facturer.
Lactate and pyruvate content in tumor tissue 
homogenates was determined by enzyme spectro-
photometry method using lactate dehydrogenase 
(Sigma, USA) [18].
The samples for biochemical study were collected 
from 4–5 animals per group, frozen and stored at 
–20 °С (blood plasma) or in liquid nitrogen (tumor tis-
sue) until the moment of analysis.
Total activity of lactate dehydrogenase (LDH) 
in tumor tissue homogenates was determined 
by the rate of NADH (Sigma, USA) oxidation registered 
by spectrophotometry by the decrease of optical den-
sity at the wavelength of 340 nm [18].
Engulfing capacity of tumor­associated СD14+ 
cells was determined by flow cytometry with the use 
of FITC-labeled staphylococcus.
Tumor­associated СD14+ cells were identi-
fied with the use of anti-СD14 antibodies (Becton 
Dickinson, USA) according to the instructions of the 
manufacturer [19].
Production of reactive oxygen species (ROS) 
in tumor-associated СD14+ cells was determined by spec-
trofluorometry with the use of 2.7-dichlorofluorescein 
diacetate (Sigma, USA) [19].
Statistical analysis of the data was performed 
by descriptive statistics, Student’s t-test and Mann — 
Whitney U test, with the use of Microsoft Excel and 
Microcal Origin programs.
RESULTS AND DISCUSSION
It has been shown that combination of DCA and 
2DG exerted significant antitumor activity, while both 
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studied compounds as single agents were practically 
inactive in inhibiting primary tumor growth. The data 
on the influence of DCA, 2DG and their combination 
on the primary tumor growth and metastasis at 21st 
day after LLC transplantation are presented in Fig. 1. 
As one may see, at this time in LLC/R9-bearing mice 
treated with DCA or 2DG the primary tumor volume 
did not differ significantly from that in control group 
(see Fig. 1). Meanwhile, DCA combined with 2DG 
significantly inhibited tumor growth starting from the 
16th day and on the 21st day tumor volume was by 70% 
(p < 0.05) lower compared to the control.
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Fig. 1. Effect of DCA, 2DG and their combination on tumor 
growth and metastasis indices in LLC/R9 bearing mice. 
*р < 0.05 as compared to the control
In regard to antimetastatic effects, only DCA but 
not 2DG suppressed metastasizing. In animals treated 
with DCA the number and volume of lung metastases 
decreased nearly by 60% (р < 0.05) and more than 
by 90% (р < 0.05), respectively, as compared to the 
control indexes. Meanwhile, no antimetastatic activity 
was revealed in 2DG treated mice (see Fig. 1). In the 
case of combined treatment of animals with 2DG and 
DCA antimetastatic effects were related to activity 
of DCA only, but not 2DG: in this group of mice the 
number and volume of lung metastases decreased 
by 46% (р < 0.05) and nearly by 90% (р < 0.05), re-
spectively, compared to the control group.
The study of lactate and pyruvate levels in the tu-
mor tissue has shown that antitumor activity of DCA 
combined with 2DG was mediated by their significant 
effect on glucose metabolism reflected in decreased 
lactate level and accumulation of pyruvate in the tumor. 
As shown in Fig. 2, combined treatment of mice with 
DCA and 2DG resulted in 31% decrease (p < 0.05) 
of lactate content and 48% increase (p < 0.05) of py-
ruvate content compared to the control values. Such 
effects could reflect the decreased utilization of pyru-
vate in the tricarboxylic acid cycle and/or decreased 
LDH activity in the reactions of pyruvate to lactate 
reduction. As far as LDH activity did not change sig-
nificantly upon combined use of DCA and 2DG (Fig. 2), 
accumulation of pyruvate could be related to the de-
creased intensity of the reactions initiated by pyruvate 
as a substrate. This could be accompanied not only 
with pyruvate accumulation, but also with an increased 
pool of NAD-H and the decreased pool of NAD+ which 
is an electron acceptor providing glycolysis function-
ing. It couldn’t be excluded that altered level of lactate 
and pyruvate in tumor tissue may be related to the 
competition between 2DG and glucose.
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Fig. 2. Effect of DCA, 2DG and their combination on lactate 
and pyruvate content and LDH activity in tumor tissue of LLC/
R9 bearing mice. *р < 0.05 as compared to the control
In the group of animals treated with DCA and 2DG, 
lactate content decreased not only in tumor tissue but 
also in blood plasma (by 38% compared to the control, 
p < 0.05, Table 1). The decrease of lactate content 
in blood plasma close to 30% (p < 0.05) was also 
observed in the group of mice treated with 2DG only 
indicating the contribution of 2DG into the decrease 
of lactate content in the tumor and blood plasma of ani-
mals treated by 2DG and DCA combination.
Table 1. Effect of DCA, 2DG and their combination on blood plasma bio-
chemical indices of LLC/R9 bearing mice
Group of mice Glucose, mM Lactate, mM Creatinine, mM Urea, mM
Control 5.3 ± 0.9 8.5 ± 0.9 31.8 ± 1.5 4.5 ± 0.5
DCA 5.7 ± 0.8 8.2 ± 0.5 38.3 ± 2.0* 3.6 ± 0.4
2DG 6.5 ± 0.3 6.2 ± 0.5* 35.4 ± 1.0 4.2 ± 0.5
DCA + 2DG 4.8 ± 1.1 5.2 ± 0.7* 33.3 ± 4.5 3.1 ± 0.6
Note: *р < 0.05 as compared to the control.
As shown in Table 1, decreased lactate content 
in blood plasma of mice treated with 2DG or 2DG com-
bined with DCA, did not affect glucose content in blood 
plasma. At the same time, in animals treated with DCA 
we have registered significant increase of creatinine 
content (р < 0.05) suggesting an ability of this com-
pound to cause kidney malfunction in tumor-bearing 
animals.
Earlier we have shown that high antitumor efficacy 
of DCA, alone or in combination with antiangiogenic 
aconitin-containing agent, against solid variant of Ehr-
lich carcinoma was related to the increased produc-
tion of ROS in СD14+ cells infiltrating the tumor with 
increased nitrosylation of proteins of mitochondrial 
ETC in tumor cells [20]. However, the studied agents 
have no effect on the functional state of mitochondrial 
ETC in LLC cells and nitrosylation levels of proteins 
of mitochondrial ETC. As one may see in Fig. 3, in LLC/
R9 bearing animals treated with DCA combined with 
2DG or DCA only, an intensity of EPR signals cor-
responding to NO-complexes of heme (gmed = 2.007) 
or nonheme (gmed = 2.03) iron in proteins of mitochon-
drial ETC were not statistically higher than analogous 
indexes in the control. Similar pattern has been ob-
served for EPR signal intensity of Fe-S cluster proteins 
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(g = 1.94), which, as it is known, characterize functional 
activity of ETC complex I: in all groups of animals this 
index was practically equal to that in the control.
Significant increase (р < 0.05) of nitrosylation level 
of heme and nonheme proteins has been registered 
only in the group of animals treated with 2DG, that may 
be attributed to a capability of this compound to modify 
the production of reactive nitrogen species [21]. How-
ever, an enhancement of antitumor activity of DCA with 
2DG was not related to its influence on mitochondrial 
ETC functioning in LLC cells.
An analysis of a functional state of tumor-infiltrating 
CD14+-macrophage like cells has shown that antitumor 
effect of DCA in combination with 2DG was realized, 
at least in part, via enhancement of their cytotoxic ac-
tivity. In the group of animals treated with DCA in com-
bination with 2DG, the level of ROS production in these 
cells increased by 120% (p < 0.01) compared with that 
in the control (Fig. 4). In these groups of animals, the 
relative number of tumor-infiltrating CD14+ cells and 
their engulfing capacity did not differ significantly from 
corresponding indexes in the control. It is necessary 
to note that in the groups of mice treated with DCA 
or 2DG the number and functional activity of CD14+ 
cells did not differ significantly from control group.
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Fig. 3. Effect of DCA, 2DG and their combination on the indices 
of functional state of MtETC in the tumor cells. *р < 0.05 as com-
pared to the control
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Fig. 4. Effect of DCA, 2DG and their combination on the indices 
of functional state of tumor-infiltrating CD14+ macrophage like 
cells. *р < 0.05 as compared to the control
Therefore, the present work has demonstrated 
significant enhancement of antitumor action of DCA 
used in combination with other inhibitor of energetic 
metabolism, 2DG, even in the absence of antitumor 
effects of these agents used at the same dosages 
in monotherapy mode. According to literature data, 
antitumor activity of DCA is largely based on its capa-
bility for negative regulation of PDK, a negative regula-
tor of enzymes of mitochondrial PDH complex, which 
plays a key role in regulation of tricarboxylic acid cycle 
and oxidative phosphorylation [22]. In the case of PDK 
inhibition with DCA, tumor cell metabolism switches 
from glycolysis to oxidative phosphorylation that 
should affect lactate production in tumor tissue. In our 
work, antitumor effectiveness of DCA in combination 
with 2DG was associated with inhibition of glycolysis, 
as it has been illustrated by the drop of lactate content 
in the tumor. However, the relation between antitumor 
activity of DCA and 2DG and their influence on tumor 
metabolism has been found only in the case of their 
combined use, supposedly due to the enhancement 
of pharmacological effects of these compounds. 
In other words, an effective inhibition of glycolysis in tu-
mor cells sufficient for realization of antitumor action 
has been exerted as a consequence of simultaneous 
intensification of oxidative phosphorylation in tumor 
cells via DCA-induced activation of PDH complex and 
competitive inhibition of glucose consumption by tu-
mor cells by 2DG, and consequently, decreased en-
ergy and/or concentration of glycolytic intermediates.
Antitumor effectiveness of DCA combined with 
2DG could be related not only to glycolysis inhibition, 
but also to their effect on tumor microenvironment, 
namely, activation of tumor-infiltrating cells expressing 
CD14 receptor [23]. Capability of DCA to affect dif-
ferent types of immunocompetent cells, in particular, 
to cause alternative activation of tumor-associated 
macrophages has been shown in several studies [24, 
25]. Our data evidenced on the capability of the studied 
agents to increase cytotoxic activity of tumor infiltrating 
CD14+ immunocompetent cells (reflected in increased 
intracellular production of ROS in these cells), while 
there was no influence of phagocytic (engulfing) ac-
tivity of the cells. Such effect on the functional state 
of CD14+ cells was observed only in the case of the 
combined use of DCA and 2DG.
At last, one should note that while DCA-based 
monotherapy was found to be insufficient for achieve-
ment of antitumor effect, DCA, but not 2DG, exerted 
an expressed antimetastatic activity against LLC/
R9. Combined use of DCA and 2DG did not enhance 
such antimetastatic effect. Antimetastatic acti vity 
of DCA has been demonstrated in other studies, 
in particular, against rat mammary adenocarcinoma 
cells if administered by intravenous route [26]. Pos-
sible mechanism of antimetastatic activity of DCA was 
discussed in the study [27], where it has been shown 
that activation of mitochondrial PDH complex in tumor 
cells significantly increased their sensitivity to anoikis 
and, correspondingly, decreased their metastatic 
potential. Taking into account high antimetastatic ac-
tivity of DCA against LLC/R9, capability of this agent 
to promote activation of PDH complex through PDK 
inhibition in tumor cells, and the data on the close re-
lation between activity of PDH complex in tumor cells 
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and their metastatic potential, one could suppose that 
DCA could be considered as a promising agent with 
high antimetastatic activity.
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